ClinicalTrials.gg
RecruitingNCT053550125A-QUIT-NUpdated Oct 25, 2023

Organization of Smoking Cessation in Pregnant Women With the Implementation of the 5A Strategy in New Aquitaine.

An interventional study of 5A organizational innovation in Smoking Cessation and Pregnancy Related, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-25.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,505
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Smoking Cessation with a site in France — 8 open to participants now, 11 under way, 1 of them phase 3. Smoking Cessation · France.

Planned enrollment
2nd of 43
4,505 · median 124
Started
2022
with 5 others
No phase
21 of 48
7 open now
Primary completion
2025-05
later than 1 of 10 live
Registered
37th of 48
by date

Among the 48 studies in Smoking Cessation with a site in France, this one is the 2nd largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2022, is one of 21 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 37th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

8 of the 48 studies in Smoking Cessation with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Smoking Cessation with a site in France, or all of them as a file.
02

Study summary

The investigators are conducting a pragmatic cluster randomized trial in stepped-wedge of which objectives are to evaluate the effectiveness and the conditions of effectiveness of an organizational strategy for smoking cessation - 5A-QUIT-N - among pregnant women in New Aquitaine (NA), by using and optimizing existing resources

Read the detailed description

In France, in 2016, 16.6% of pregnant women were smokers, the highest levels among European countries. Pregnancy is considered a teachable moment for smoking cessation. There are many tools, interventions and programs to reduce the smoking habits of pregnant women. The challenge is therefore not to propose new interventions but to understand what is hindering the implementation of existing interventions and proposing corrective measures. In this context, the scientific literature shows that interventions for smoking pregnant women only seem effective when based on a comprehensive approach that combines multiple interventions. In particular, interventions based on the 5A's model (Ask, Advise, Assess, Assist, Arrange) are largely recommended and have shown their effectiveness abroad. Factors facilitating or hindering the implementation of such strategies are mainly organizational. As organizations are context-dependent by nature, considering the generalization of such strategies in France therefore requires adapting them to the French health system and evaluating them in context, in a pragmatic approach, inserted into routine care and using the tools, procedures and existing organizations in the territories.

03

Conditions studied

  • Smoking Cessation
  • Pregnancy Related

Browse trials for

Keywords

  • Smoking cessation
  • Pregnancy
  • 5As
  • Healthcare optimization
  • Transferability
  • Healthcare sustainability
  • Organizational innovation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

In this research, there are 4 categories of research participants:

  • Healthcare professionals: the target of the 5A-QUIT-N intervention from whom data will be collected to meet the secondary objective of the effectiveness conditions.
  • Stakeholders: individuals involved in the implementation of the research and intervention from whom data will be collected to meet the secondary objective of the effectiveness conditions.
  • Women who have just given birth and who smoke tobacco in early pregnancy: indirect beneficiaries of the intervention, from whom data will be collected to meet the primary objective of effectiveness.
  • Co-parent (partner) of the new-born child of the woman who has just given birth included in the study

Inclusion criteria

Inclusion criteria for the intervention

The inclusion criteria for the clusters are :

  • Territory of maternity attractiveness in New Aquitaine

The inclusion criteria for care providers within the clusters are:

  • All institutions, structures and organizations and health professionals likely to participate in the follow-up of pregnant women
  • All institutions, structures and organizations and health professionals specializing in addictology or tobaccoology

The inclusion criteria for pregnant women within the clusters are :

  • All pregnant women who have smoked tobacco (at least 2 times a week, for at least 1 week) during the pregnancy (including the period when she was unaware of the pregnancy)

Inclusion criteria for the primary objective measures:

The inclusion criteria for women are (for data collection):

  • Have given birth in a New Aquitaine maternity hospital,
  • Reside in New Aquitaine
  • To have been followed for the pregnancy in the territory of the maternity of delivery
  • To have used tobacco during (at least 2 times a week, for at least 1 week) the pregnancy (including the period when she was unaware of the pregnancy)
  • Be over 18
  • Have given free, informed and express consent

Exclusion criteria

  • Exclusion criteria:

Non-inclusion criteria for the intervention

Cluster non-inclusion criteria:

  • Pilot territory (territory of attractiveness of the Arcachon maternity hospital)
  • Impossibility of collecting the main judgment criterion in the cluster Within these clusters, the health care providers and the pregnant women are all concerned and therefore do not have any non-inclusion criteria.

Non-inclusion criteria of measures for the primary objective:

The criteria for non-inclusion of women who have just given birth are:

  • Not speaking French,
  • Have COVID during delivery
  • Use only electronic cigarettes,
  • Under legal protection (guardianship, curatorship, safeguard of justice)
  • Women giving birth under X
  • Women giving birth to a stillborn baby
  • Women having made a denial of pregnancy
  • Women who have their child in neonatal intensive care
  • Women who have been fully monitored for their pregnancy outside of New Aquitaine
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
4,505 participants (estimated)

Study arms

  • Experimental
    5A-QUIT-N intervention

    The 5A-QUIT-N intervention can be defined as multilevel, i.e., it is based on a territorial organization with expected results at the level of professional practice (structuring of practices around the 5A method) and therefore of the care of pregnant women who smoke tobacco. This project is based on three strategic axes: * A gradation of the care offer * Personalized care by developing specific treatment paths * Coordination of territorial resources to support pregnant women in quitting smoking. These elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population.

    Other: 5A organizational innovation

  • No intervention
    5A-QUIT-N control

    Usual care in the care of pregnant women who smoke tobacco.

Interventions

  • Other5A organizational innovation

    This project is based on three strategic axes: * A gradation of the care offer allowing to adapt the means and resources mobilized on the territory * Personalized care by developing specific treatment paths based on the risk factors and/or vulnerabilities of the pregnant woman * Coordination of territorial resources to support pregnant women in quitting smoking These three key elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population.

06

What researchers measure

Primary outcomes

  1. Tobacco abstinence at delivery

    The point prevalence of abstinence at delivery, which is the proportion of women reporting abstinence from smoking for at least 7 days at delivery. This criterion is well documented in the literature assessing tobacco use. It has the advantage of detecting the delayed effects of an intervention and can be easily extrapolated.

    Time frame: At delivery (smoking status of the previous 7 days)

Secondary outcomes

  1. Average number of cigarettes smoked at inclusion

    Average number of cigarettes smoked per day over the last 30 (or 7) days

    Time frame: At inclusion

  2. Average number of cigarettes smoked at postpartum

    Average number of cigarettes smoked per day over the last 30 (or 7) days

    Time frame: 6 months and 1 year after delivery

  3. Attempts to reduce tobacco consumption

    The number of attempts to reduce tobacco consumption (at least 1 cigarette)

    Time frame: 1 to 3 days after delivery

  4. Attempts to quit smoking

    Number of attempts to quit smoking (at least 24 hours)

    Time frame: 1 to 3 days after delivery

  5. Continuous abstinence

    Continuous abstinence (in number of days)

    Time frame: 1 to 3 days after delivery

  6. Birth weight

    Birth weight (in kg) of the baby

    Time frame: At baby birth, up to 3 days after delivery

  7. Gestational age

    Gestational age (in months) of the baby (at birth).

    Time frame: At baby birth, up to 3 days after delivery

  8. Sustainability of professional practices

    Prevalence of completion of each A of the 5A approach evaluated on a subgroup of women who have just given birth at a distance from the deployment of the intervention (18 months) via the questionnaire

    Time frame: 18 months from the deployment of the intervention

  9. Sustainability of the impact on health

    Prevalence of women smoking tobacco at delivery over the last 7 days via two sources: the computer systems of the maternity units that have this information systematically (non-exhaustive because not all maternity units in the New Aquitaine region have a computer system) and on a sub-group of women who have just given birth

    Time frame: 18 months from the deployment of the intervention

  10. Postpartum relapse rate at 6 months

    Relapse rate among women who quit smoking during pregnancy at 6 and 12 months postpartum defined as a resumption of at least 7 consecutive days of smoking in the past 6 months.

    Time frame: At 6 months postpartum

  11. Postpartum relapse rate at 12 months

    Relapse rate among women who quit smoking during pregnancy at 6 and 12 months postpartum defined as a resumption of at least 7 consecutive days of smoking in the past 6 months.

    Time frame: At 12 months postpartum

  12. Continued abstinence

    Continued abstinence (in number of days)

    Time frame: 6 months and 1 year after delivery

  13. Implementation of intervention

    Barriers and levers to implementation in professionals

    Time frame: Through study completion, an average of 3 years

  14. Conditions of transferability

    Conditions of transferability linked to the characteristics of the stakeholders and the context: contextual conditions for success within the centres, the characteristics of professionals and patients influencing outcomes

    Time frame: Through study completion, an average of 3 years

  15. Viability

    Assessment of intervention deployment in a real-world setting, using 5 criteria: utility, affordability, evaluability, adaptability and acceptability. "Utility" dimension (as a complement to the secondary criteria) of viability through the recovery mechanisms identified as successful mental health recovery Affordability for professionals and beneficiaries (financial, geographical, social and cultural levers and brakes of the intervention) Evaluability of 5A-QUIT-N: carrying out this evaluation, the availability of professionals and beneficiaries to answer questionnaires and interviews, missing data in the questionnaires etc. Adaptability of 5A-QUIT-N: integration of the action into the context and the current organisation of the centres Acceptability of 5A-QUIT-N: by professionals and beneficiaries

    Time frame: Through study completion, an average of 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for May 2025, 31 months after the start.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 31 months is above that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2022
First posted
May 2, 2022
StartActual
Oct 3, 2022
Primary completionEst.
May 31, 2025
CompletionEst.
May 31, 2026
Last update
Oct 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05355012
Responsible party
Sponsor
First posted
May 2, 2022
Start date
Oct 3, 2022
Primary completion
May 31, 2025 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Oct 25, 2023

Study contacts

François Alla, Prof
Contact
francois.alla@u-bordeaux.fr
+335 57 82 26 50
Charlotte Kervran
Contact
charlotte.kervran@u-bordeaux.fr
François Alla, Prof
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion